文献速递生殖医学妇科

1型神经纤维瘤病的胚胎植入前遗传学检测:分子遗传学方面及对生殖咨询的影响

Preimplantation genetic testing for neurofibromatosis type 1: molecular genetic aspects and impact on reproductive counseling.
PubMed 文献 · Hum Reprod · 2026-01-01

该回顾性观察性队列研究在三个大型胚胎植入前遗传学检测(PGT)中心纳入281对夫妇,分析1型神经纤维瘤病(NF1)的PGT分子设计与生殖咨询。研究发现散发案例中8%存在嵌合体,多外显子缺失患者嵌合体比例显著高于单核苷酸变异患者(P<0.001),并据此构建了NF1生殖咨询与PGT设计的流程图。

要点

  • 散发NF1病例中嵌合体发生率为8%(13/168),其中约半数(6/13)在PGT前未知。
  • 多外显子缺失患者的嵌合体比例显著高于SNV患者(P<0.001,Fisher精确检验)。
  • 两个复发性SNV与嵌合体显著相关(P<0.0167,Fisher精确检验)。

核心结论

  • NF1的嵌合体发生率与多外显子缺失及特定SNV相关,该发现被结构化为流程图以指导NF1生殖咨询、PGT设计和PGT治疗。

研究设计与样本

  • 回顾性观察性队列研究,在三个大型PGT中心纳入281对夫妇,涵盖218种不同NF1变异,时间自2004年首个NF1检测方法建立至2022年。
  • 采用PCR-based PGT(短串联重复标记,n=230)、SNP-array-based PGT(n=39)和NGS-based PGT(n=12);SNV采用minisequencing(SNAPshot)或D-ARMS整合,小缺失和插入采用片段长度分析。
  • 所有PGT检测按本地方案和ESHRE指南设计并验证;新描述的76种变异按ACMG/AMP分类系统评分并在发表前提交至LOVD。

主要发现

  • 散发案例中嵌合体存在比例为8%(n=13/168),其中约一半在PGT前未知(n=6/13)。
  • 多外显子缺失患者嵌合体比例(n=4/6)显著高于SNV患者(n=9/162)(P<0.001,Fisher精确检验)。
  • 两个复发性SNV与嵌合体显著相关(P<0.0167,Fisher精确检验)。
  • 鉴定出三个不相关家系,其近亲携带不同NF1变异。

临床怎么用

  • 作者认为该发现对NF1夫妇的生殖咨询有实质性影响,有助于知情生殖决策。
  • 作者认为该发现提醒全球同行注意NF1特异的PGT分子设计与治疗中的陷阱。

局限性

  • 由于回顾性设计,部分病例(n=6)的基因检测结果和临床表型细节无法获取。
  • 研究结果对全球中心的适用程度取决于当地操作流程和法规。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: How do the genetic complexities of neurofibromatosis type 1 (NF1) impact reproductive counseling, preimplantation genetic testing (PGT) design, and PGT treatment? SUMMARY ANSWER: We established association between both incidence and tissue mosaicism with multiple exon deletions and specific single-nucleotide variants (SNVs) in neurofibromin 1 (NF1), a clinical actionable finding that we structured as a flowchart outlining challenges in and an approach for reproductive counseling, PGT design, and PGT treatment for NF1. WHAT IS KNOWN ALREADY: NF1 has a prevalence of 1 in 2500-3000 and is one of the most frequently requested autosomal dominant indications for PGT. NF1 is a large gene with a high mutation rate, resulting in a 50% de novo occurrence, many different reported variants scattered across the gene and relatively frequent mosaicism. STUDY DESIGN, SIZE, DURATION: We conducted a retrospective, observational cohort study on PGT molecular design for NF1 in three large PGT centers (n = 281 couples), starting from the first assay for NF1 developed in 2004 until 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS: A PGT assay was developed for 281 couples with 218 different variants in NF1. Newly described variants (n = 76) were scored using the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) classification system and submitted prior to publication in the Leiden Open Variation Database (LOVD). The employed techniques were PCR-based PGT using short tandem repeat markers (n = 230), SNP-array-based PGT (n = 39), and next-generation sequencing (NGS)-based PGT (n = 12). Minisequencing (SNAPshot) or double amplification refractory mutation system (D-ARMS) was used to incorporate SNVs. Small deletions and insertions were incorporated using fragment length analysis. All PGT assays were designed and validated according to local protocols and ESHRE guidelines. MAIN RESULTS AND THE ROLE OF CHANCE: Mosaicism was present in 8% of the sporadic cases (n = 13/168), of which about half were unknown prior to PGT (n = 6/13). Mosaicism was significantly higher in patients with multiple exon deletions (n = 4/6) as compared to patients with SNVs (n = 9/162) (P < 0.001, Fisher's exact test). Additionally, two recurrent SNVs were significantly associated with mosaicism (P <0.0167, Fisher's exact test). Importantly, three unrelated families with different NF1 variants in close relatives were identified. LIMITATIONS, REASONS FOR CAUTION: Due to its retrospective design, not all details on the genetic test results and clinical phenotype could be retrieved for some cases (n = 6). The extent to which our findings are applicable to centers worldwide depends on their local procedures and legislation. WIDER IMPLICATIONS OF THE FINDINGS: Our findings substantially impact reproductive counseling for couples with NF1, enabling informed reproductive decision-making. For couples affected with NF1 proceeding with PGT, our findings alert colleagues worldwide on NF1-specific pitfalls in PGT molecular design and treatment. STUDY FUNDING/COMPETING INTEREST(S): There was no funding involved in the research for this publication. M.Z.E. is an inventor on two patent applications: ZL910050-PCT/EP2011/060211-WO/2011/157846 'Methods for haplotyping single cells' and ZL913096-PCT/EP2014/068315-WO/2015/028576 'Haplotyping and copy-number typing using polymorphic variant allelic frequencies'. The other authors have no competing interests to disclose. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Vernimmen V, De Rycke M, Moutou C, et al. Preimplantation genetic testing for neurofibromatosis type 1: molecular genetic aspects and impact on reproductive counseling. Hum Reprod. 2026. PMID: 41289058. doi:10.1093/humrep/deaf224

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。